Gene:
NPM1
nucleophosmin (nucleolar phosphoprotein B23, numatrin)

PharmGKB contains no dosing guidelines for this gene. To report known dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB contains no drug labels with pharmacogenomic information for this gene. To report a drug label with PGx, click here.

PharmGKB contains no clinical annotations for this gene. To report clinical variants, click here.

PharmGKB contains no genetic tests for this gene. To report genetic tests, click here.

Overview

Alternate Names:  Nucleophosmin 1 (nucleolar phosphoprotein B23, numatrin); nucleolar phosphoprotein B23; nucleolar protein NO38; nucleophosmin; nucleophosmin 1; nucleophosmin/nucleoplasmin family, member 1; numatrin
Alternate Symbols:  B23; MGC104254; NPM; NUMATRIN
PharmGKB Accession Id: PA31712

Details

Cytogenetic Location: chr5 : q35.1 - q35.1
GP mRNA Boundary†: chr5 : 170814798 - 170837888
GP Gene Boundary†: chr5 : 170804798 - 170840888
Strand: plus
Product Name: No data available
† The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.

PharmGKB Curated Pathways

Pathways created internally by PharmGKB based primarily on literature evidence.

PharmGKB contains no curated pathways for this gene. If you would like to volunteer to work on a pathway, please let us know.

External Pathways

Links to non-PharmGKB pathways.

  1. Aurora B signaling - (Pathway Interaction Database NCI-Nature Curated)
  2. BARD1 signaling events - (Pathway Interaction Database NCI-Nature Curated)
  3. HIF-1-alpha transcription factor network - (Pathway Interaction Database NCI-Nature Curated)

Publications related to NPM1: 6

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Association of ABCB1 polymorphisms with survival and in vitro cytotoxicty in de novo acute myeloid leukemia with normal karyotype. The pharmacogenomics journal. 2010. Gréen H, et al. [Article:20938465@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Population-specific genetic variants important in susceptibility to cytarabine arabinoside cytotoxicity. Blood. 2009. Hartford Christine M, et al. [Article:19109566@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Interaction of cyclooxygenase-2 variants and smoking in pancreatic cancer: a possible role of nucleophosmin. Gastroenterology. 2009. Zhao Dan, et al. [Article:19422084@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenomics in acute myeloid leukemia. Pharmacogenomics. 2009. Roumier Christophe, et al. [Article:19891558@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Recurring mutations found by sequencing an acute myeloid leukemia genome. The New England journal of medicine. 2009. Mardis Elaine R, et al. [Article:19657110@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. The New England journal of medicine. 2008. Schlenk Richard F, et al. [Article:18450602@PubMed]
PharmGKB® is a registered trademark of HHS and is financially supported by NIH/NIGMS. It is managed at Stanford University (R24 GM61374).
©2001-2012 PharmGKB.